2.2. Analysis.
Comparison 2 Leukotriene Receptor Antagonists (LTRA) + ICS vs. DOUBLE dose of ICS in SYMPTOMATIC PATIENTS, Outcome 2 Patients with 1 or more exacerbations requiring systemic steroids at HIGHER THAN LICENSED DOSES.
Comparison 2 Leukotriene Receptor Antagonists (LTRA) + ICS vs. DOUBLE dose of ICS in SYMPTOMATIC PATIENTS, Outcome 2 Patients with 1 or more exacerbations requiring systemic steroids at HIGHER THAN LICENSED DOSES.